pembrolizumab + carboplatin + gemcitabine

Pembrolizumab + carboplatin + gemcitabine is an investigational combination regimen for cancer therapy, primarily studied in metastatic triple-negative breast cancer (TNBC)[2][3][5]. Pembrolizumab is a monoclonal antibody checkpoint inhibitor targeting the programmed death receptor-1 (PD-1) on T cells and is designed to enhance anti-tumor immunity by blocking PD-1 mediated immune suppression[4]. Carboplatin is a platinum-based chemotherapeutic agent that induces apoptosis by forming DNA crosslinks, thereby preventing replication and transcription. Gemcitabine is a nucleoside analog chemotherapeutic that incorporates into DNA during replication, causing chain termination and cell death. This combination is intended to provide synergistic effects by both directly inhibiting cancer cell division (chemotherapy) and boosting immune recognition and destruction of tumor cells (immunotherapy)[2][5]. It is under clinical investigation for metastatic breast cancer and has shown benefits such as tumor shrinkage, improved progression-free survival, and overall survival in clinical trials[1][2][3][5].

Brand names

Keytruda (pembrolizumab)Gemzar (gemcitabine)carboplatin + gemcitabine + pembrolizumab

Other names

pembrolizumab + carboplatin + gemcitabinepembrolizumab + gemcitabine + carboplatin